Stock Track | Gilead Sciences Soars 5.02% Intraday on HSBC Upgrade and Positive Developments

Stock Track03:56

Gilead Sciences' stock soared 5.02% during Tuesday's intraday session, driven by positive analyst action and company developments.

The surge was catalyzed by HSBC's upgrade of the stock from Hold to Buy, with a target price increase from $133 to $155, implying approximately 15% upside. This upgrade reflects growing confidence in the company's outlook amid several positive developments.

Gilead has recently completed its $7.8 billion acquisition of Arcellx, received FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and reported a Q1 earnings beat. The company also raised full-year guidance for Yeztugo to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion. Broader Wall Street sentiment remains positive, with FactSet consensus showing an average analyst target price of $160.74 and an overall Buy rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165857129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 03:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165857129","market":"us","top_or_hot":-1,"title":"Stock Track | Gilead Sciences Soars 5.02% Intraday on HSBC Upgrade and Positive Developments","media":"Stock Track","content":"<p>Gilead Sciences' stock soared 5.02% during Tuesday's intraday session, driven by positive analyst action and company developments.</p><p>The surge was catalyzed by HSBC's upgrade of the stock from Hold to Buy, with a target price increase from $133 to $155, implying approximately 15% upside. This upgrade reflects growing confidence in the company's outlook amid several positive developments.</p><p>Gilead has recently completed its $7.8 billion acquisition of Arcellx, received FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and reported a Q1 earnings beat. The company also raised full-year guidance for Yeztugo to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion. Broader Wall Street sentiment remains positive, with FactSet consensus showing an average analyst target price of $160.74 and an overall Buy rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Gilead Sciences Soars 5.02% Intraday on HSBC Upgrade and Positive Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Gilead Sciences Soars 5.02% Intraday on HSBC Upgrade and Positive Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-08 03:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences' stock soared 5.02% during Tuesday's intraday session, driven by positive analyst action and company developments.</p><p>The surge was catalyzed by HSBC's upgrade of the stock from Hold to Buy, with a target price increase from $133 to $155, implying approximately 15% upside. This upgrade reflects growing confidence in the company's outlook amid several positive developments.</p><p>Gilead has recently completed its $7.8 billion acquisition of Arcellx, received FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and reported a Q1 earnings beat. The company also raised full-year guidance for Yeztugo to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion. Broader Wall Street sentiment remains positive, with FactSet consensus showing an average analyst target price of $160.74 and an overall Buy rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1165857129","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165857129","pubTimestamp":1783454213,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Gilead Sciences' stock soared 5.02% during Tuesday's intraday session, driven by positive analyst action and company developments.The surge was catalyzed by HSBC's upgrade of the stock from Hold to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"个股追踪|吉利德科学盘中大涨5.02%因汇丰升级及利好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"Gilead Sciences' stock soared 5.02% during Tuesday's intraday session, driven by positive analyst action and company developments.The surge was catalyzed by HSBC's upgrade of the stock from Hold to Buy, with a target price increase from $133 to $155, implying approximately 15% upside. This upgrade reflects growing confidence in the company's outlook amid several positive developments.Gilead has recently completed its $7.8 billion acquisition of Arcellx, received FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and reported a Q1 earnings beat. The company also raised full-year guidance for Yeztugo to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion. Broader Wall Street sentiment remains positive, with FactSet consensus showing an average analyst target price of $160.74 and an overall Buy rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165857129","isCrawlerRequest":true}